You can apply for academically led translational projects that aim to improve prevention, diagnosis, prognosis or treatment of significant health needs, or to develop research tools that increase the efficiency of developing interventions. All diseases and interventions are eligible for support. You can also address global health issues.
Support is available for the following stages of development:
- prototype discovery and design
- pre-clinical testing of novel interventions
- early-phase clinical studies of novel interventions (phases 1 and 2a).
Your projects can start and finish at any point. You can submit follow-on proposals where you can justify the need for continued support.
You can apply for funding for work in:
- candidate therapeutic entities, for example drug discovery
- vaccines for infectious or non-infectious disease
- novel biologics (antibodies, peptides, proteins)
- advanced therapeutics (gene therapy, T-cell therapy, etc)
- regenerative medicine
- repurposing clinical studies, using existing therapies for new indications
- novel devices
- diagnostics (including biomarker validation)
- novel medical imaging technology
- new surgical techniques or tools
- behavioural and psychological interventions
- digital healthcare, app development, enabled devices, artificial intelligence enabled diagnosis
- radiotherapy and radiation protocols
- interventions that benefit health in low- and middle-income countries.
This funding opportunity will not support:
There is no limit to the amount of funding you can apply for or the length of your project. You should instead justify the timescale and resources needed in the context of the proposed work.
We encourage working with charities or industry where these partnerships can add value to the project, for example in terms of access to expertise, technologies, reagents or funding. Please note that collaboration is not a prerequisite for application.
Applications involving collaboration with industry should consult the MRC industry collaboration agreement. Please note that we do not fund the work of your industrial partners.